Fumio Imamura - Concepedia

Author

Fumio Imamura

Osaka International Cancer Institute ORCID

Also Known As

F Imamura, F. Imamura, FUMIO IMAMURA, Fumio IMAMURA, Fumio Imamura, Fumiya Imamura, Imamura Fumio, Mithra Baliga, Riichiro Hira

401

Publications

22.3K

Citations

H-Index

Concepts

All Affiliations

Osaka International Cancer Institute Osaka Prefectural Medical Center The University of Osaka Kyoto University Kindai University

About

Fumio Imamura is an author at Osaka International Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	63	5.6K
2	Health Sciences	15	18	1K
3	Engineering	3	3	361
4	Public Health	1	1	64
5	Biochemistry	1	1	22

Fumio Imamura

136

Publications

21.1K

Citations

H-Index

Page 1

	Year	Citations
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, New England Journal of Medicine	2017	5K
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok, Yi‐Long Wu, Iveta Kudaba, The Lancet	2019	3.2K
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, New England Journal of Medicine	2019	2.7K
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, The Lancet MedicineRandomised Phase 3PathologyAlectinib Versus CrizotinibBronchial Neoplasm	2017	895
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, The Lancet Oncology MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncology	2019	594
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, The Lancet Oncology MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment	2018	568
Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection Yohei Miyagi, Masahiko Higashiyama, Akira Gochi, PLoS ONE	2011	439
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer Riichiroh Maruyama, Yutaka Nishiwaki, Tomohide Tamura, Journal of Clinical Oncology	2008	364
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study Suresh S. Ramalingam, Yi Cheng, C. Zhou, Annals of Oncology BiologyPhysiologyPreliminary DataFirst-line Osimertinib	2018	352
Quantitative Detection of <i>EGFR</i> Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas Kazuya Taniguchi, Junji Uchida, Kazumi Nishino, Clinical Cancer Research	2011	314

Page 1